Cidofovir, a synthetic antiviral agent with the CAS number 113852-37-2, is a significant therapeutic option for individuals battling severe viral infections. Its primary application lies in the treatment of Cytomegalovirus (CMV) infections, particularly CMV retinitis, a serious ocular condition affecting immunocompromised patients, often those with advanced HIV/AIDS. As a nucleoside analogue, Cidofovir works by entering infected cells and being converted into its active diphosphate form. This metabolite then interferes with viral DNA synthesis by inhibiting the viral DNA polymerase. This disruption of viral replication makes it a powerful tool in controlling infections that can otherwise have devastating consequences.

The efficacy of Cidofovir in combating CMV has led to its widespread use in clinical settings for patients who are not responding to or cannot tolerate other antiviral medications. However, the utility of Cidofovir is not confined to systemic viral infections. There is growing interest and evidence supporting its use in dermatology for various viral skin conditions. Topical formulations of Cidofovir have shown promising results in treating human papillomavirus (HPV) infections, such as anogenital warts and common warts. It has also been investigated for its effectiveness against molluscum contagiosum. These applications are still considered off-label in many regions but represent a significant expansion of Cidofovir's therapeutic potential. When considering the purchase of Cidofovir, it is important to look for reliable manufacturers and suppliers who can guarantee the purity and quality of the product. Understanding the price and sourcing options from reputable chemical companies is key to obtaining this vital medication. For those involved in research or clinical practice, securing a dependable supply chain for Cidofovir is paramount to ensuring patient access to effective treatment.